Abdul Aziz Baba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Abdul Aziz Baba has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Afshan Sumera
AUC Medicine, School of Medicine & Dentistry, University of Lancashire, Preston, United Kingdom
2 shared publications - Ammu Kutty Radhakrishnan
Jeffrey Cheah School of Medicine and Health Sciences Monash University Malaysia, Jalan Lagoon Selatan Sunway City Malaysia
2 shared publications - Soon Keng Cheong
M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman - Kampus Sungai Long, Kajang, Selangor, Malaysia
2 shared publications - Azlan Husin
Department of Internal Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian 16150, Kelantan, Malaysia
1 shared publication Goh Ai Sim
Hospital Pulau Pinang, Malaysia
1 shared publication- Marjanu Hikmah Elias
Faculty of Medicine & Health Sciences, Universiti Sains Islam Malaysia, Nilai 71800, Negeri Sembilan, Malaysia
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Hematology
- Vol. 2026 (1)
Proteomic Evidence of Complement and Coagulation Pathway Dysregulation in Transfusion‐Dependent Thalassemia
Transfusion‐dependent thalassemia (TDT) is characterized by chronic hemolysis, ineffective erythropoiesis, and iron overload, resulting in persistent oxidative stress and systemic inflammation. Patients with TDT are also at increased risk of thromboembolic complications, suggesting disturbance of hemostatic and immune‐related pathways. However, the molecular links between hemolysis, complement‐associated pathways, and coagulation abnormalities remain incompletely defined. In this study, quantitative serum proteomics was used to identify differentially expressed proteins in patients with TDT compared with healthy controls. Pathway enrichment and network analyses demonstrated coordinated alterations in proteins associated with complement regulation, coagulation pathways, lipid transport, and regulatory mechanisms. Complement component C3 and prothrombin showed increased abundance, whereas several regulatory and heme‐scavenging proteins, including alpha‐2‐macroglobulin, hemopexin, and ceruloplasmin, were reduced in TDT patients. Selected proteins were further evaluated using ELISA validation, which supported the direction of the proteomic findings. Overall, these results identify a serum proteomic profile consistent with perturbation of complement and coagulation‐related pathways in TDT in the context of chronic hemolysis and oxidative stress. This system‐level view provides additional insight into thromboinflammatory mechanisms in TDT and supports further investigation of these pathways as potential biomarkers of disease severity.
- 1 January 2026
- Published by Wiley in Advances in Hematology
- Vol. 2026 (1)
Open AccessProteomic Evidence of Complement and Coagulation Pathway Dysregulation in Transfusion‐Dependent Thalassemia
Transfusion‐dependent thalassemia (TDT) is characterized by chronic hemolysis, ineffective erythropoiesis, and iron overload, resulting in persistent oxidative stress and systemic inflammation. Patients with TDT are also at increased risk of thromboembolic complications, suggesting disturbance of hemostatic and immune‐related pathways. However, the molecular links between hemolysis, complement‐associated pathways, and coagulation abnormalities remain incompletely defined. In this study, quantitative serum proteomics was used to identify differentially expressed proteins in patients with TDT compared with healthy controls. Pathway enrichment and network analyses demonstrated coordinated alterations in proteins associated with complement regulation, coagulation pathways, lipid transport, and regulatory mechanisms. Complement component C3 and prothrombin showed increased abundance, whereas several regulatory and heme‐scavenging proteins, including alpha‐2‐macroglobulin, hemopexin, and ceruloplasmin, were reduced in TDT patients. Selected proteins were further evaluated using ELISA validation, which supported the direction of the proteomic findings. Overall, these results identify a serum proteomic profile consistent with perturbation of complement and coagulation‐related pathways in TDT in the context of chronic hemolysis and oxidative stress. This system‐level view provides additional insight into thromboinflammatory mechanisms in TDT and supports further investigation of these pathways as potential biomarkers of disease severity.
- Open Access
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1) , 2179600
Dysregulation of Ceruloplasmin, α2‐Macroglobulin, and Alpha‐2‐HS‐Glycoprotein in Transfusion‐Dependent Thalassemia
Transfusion‐dependent thalassemia (TDT) is a severe inherited anemia characterized by impaired synthesis of hemoglobin chains. Disease progression and TDT severity are potentially linked to oxidative stress and protein damage. This study aimed to explore the expression patterns of ceruloplasmin (CP), α2‐macroglobulin (A2M), and alpha‐2‐HS‐glycoprotein (AHSG) in TDT serum through quantitative proteomic profiling. The results were validated using enzyme‐linked immunosorbent assays (ELISA). The study participants were divided into three groups based on the duration of blood transfusion. Age and gender‐matched normal individuals served as controls. The results revealed the downregulation of these proteins. The reduced levels of these proteins may contribute to tissue damage in TDT patients, primarily due to increased oxidative stress. For example, decreased CP levels can disrupt iron and copper metabolism, leading to heightened oxidative stress and rendering red blood cell membranes more susceptible to rupture due to active oxygen radicals. In summary, CP, A2M, and AHSG association with iron metabolism, inflammation, and oxidative stress underscores their potential relevance in understanding TDT’s pathogenesis and progression. These findings may pave the way for improved diagnostic and therapeutic strategies for TDT patients.
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1) , 2179600
Open AccessDysregulation of Ceruloplasmin, α2‐Macroglobulin, and Alpha‐2‐HS‐Glycoprotein in Transfusion‐Dependent Thalassemia
Transfusion‐dependent thalassemia (TDT) is a severe inherited anemia characterized by impaired synthesis of hemoglobin chains. Disease progression and TDT severity are potentially linked to oxidative stress and protein damage. This study aimed to explore the expression patterns of ceruloplasmin (CP), α2‐macroglobulin (A2M), and alpha‐2‐HS‐glycoprotein (AHSG) in TDT serum through quantitative proteomic profiling. The results were validated using enzyme‐linked immunosorbent assays (ELISA). The study participants were divided into three groups based on the duration of blood transfusion. Age and gender‐matched normal individuals served as controls. The results revealed the downregulation of these proteins. The reduced levels of these proteins may contribute to tissue damage in TDT patients, primarily due to increased oxidative stress. For example, decreased CP levels can disrupt iron and copper metabolism, leading to heightened oxidative stress and rendering red blood cell membranes more susceptible to rupture due to active oxygen radicals. In summary, CP, A2M, and AHSG association with iron metabolism, inflammation, and oxidative stress underscores their potential relevance in understanding TDT’s pathogenesis and progression. These findings may pave the way for improved diagnostic and therapeutic strategies for TDT patients.
- Open Access
- 26 December 2012
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-7
HOXA4Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients has emerged as a significant clinical problem. The observation that increased epigenetic silencing of potential tumor suppressor genes correlates with disease progression in some CML patients treated with IM suggests a relationship between epigenetic silencing and resistance development. We hypothesize that promoter hypermethylation ofHOXA4could be an epigenetic mechanism mediating IM resistance in CML patients. Thus a study was undertaken to investigate the promoter hypermethylation status ofHOXA4in CML patients on IM treatment and to determine its role in mediating resistance to IM. Genomic DNA was extracted from peripheral blood samples of 95 CML patients (38 good responders and 57 resistant) and 12 normal controls. All samples were bisulfite treated and analysed by methylation-specific high-resolution melt analysis. Compared to the good responders, theHOXA4hypermethylation level was significantly higher () in IM-resistant CML patients. On comparing the risk,HOXA4hypermethylation was associated with a higher risk for IM resistance (OR 4.658; 95% CI, 1.673–12.971;). Thus, it is reasonable to suggest that promoter hypermethylation ofHOXA4gene could be an epigenetic mechanism mediating IM resistance in CML patients.- 26 December 2012
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-7
Open AccessHOXA4Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients
Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients has emerged as a significant clinical problem. The observation that increased epigenetic silencing of potential tumor suppressor genes correlates with disease progression in some CML patients treated with IM suggests a relationship between epigenetic silencing and resistance development. We hypothesize that promoter hypermethylation ofHOXA4could be an epigenetic mechanism mediating IM resistance in CML patients. Thus a study was undertaken to investigate the promoter hypermethylation status ofHOXA4in CML patients on IM treatment and to determine its role in mediating resistance to IM. Genomic DNA was extracted from peripheral blood samples of 95 CML patients (38 good responders and 57 resistant) and 12 normal controls. All samples were bisulfite treated and analysed by methylation-specific high-resolution melt analysis. Compared to the good responders, theHOXA4hypermethylation level was significantly higher () in IM-resistant CML patients. On comparing the risk,HOXA4hypermethylation was associated with a higher risk for IM resistance (OR 4.658; 95% CI, 1.673–12.971;). Thus, it is reasonable to suggest that promoter hypermethylation ofHOXA4gene could be an epigenetic mechanism mediating IM resistance in CML patients.